Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?

Inzucchi SE, Abdul Ghani R, Deanfield J, Emerson S, Engelmann MDM, Hovingh GK, Jeppesen OK, Kellerer M, Mandavya K, Mann JF, Marx N, Mathieu C, McGuire DK, Mohan V, Mulvagh SL, Pop-Busui R, Poulter NR, Rasouli N, Sejersten Ripa M, Roman G, Sánchez García R, Shechter M, Buse JB

Open source

DOI: 10.1210/clinem/dgag290
Published: 2026 Jul 21
Container: The Journal of clinical endocrinology and metabolism
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1210/clinem/dgag290,
  title = {Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?},
  author = {Inzucchi SE and Abdul Ghani R and Deanfield J and Emerson S and Engelmann MDM and Hovingh GK and Jeppesen OK and Kellerer M and Mandavya K and Mann JF and Marx N and Mathieu C and McGuire DK and Mohan V and Mulvagh SL and Pop-Busui R and Poulter NR and Rasouli N and Sejersten Ripa M and Roman G and Sánchez García R and Shechter M and Buse JB},
  year = {2026},
  journal = {The Journal of clinical endocrinology and metabolism},
  doi = {10.1210/clinem/dgag290},
  url = {https://doi.org/10.1210/clinem/dgag290}
}

RIS

TY  - JOUR
TI  - Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?
AU  - Inzucchi SE
AU  - Abdul Ghani R
AU  - Deanfield J
AU  - Emerson S
AU  - Engelmann MDM
AU  - Hovingh GK
AU  - Jeppesen OK
AU  - Kellerer M
AU  - Mandavya K
AU  - Mann JF
AU  - Marx N
AU  - Mathieu C
AU  - McGuire DK
AU  - Mohan V
AU  - Mulvagh SL
AU  - Pop-Busui R
AU  - Poulter NR
AU  - Rasouli N
AU  - Sejersten Ripa M
AU  - Roman G
AU  - Sánchez García R
AU  - Shechter M
AU  - Buse JB
PY  - 2026
JO  - The Journal of clinical endocrinology and metabolism
DO  - 10.1210/clinem/dgag290
UR  - https://doi.org/10.1210/clinem/dgag290
ER  -

APA

SE, I., R, A. G., J, D., S, E., MDM, E., GK, H., OK, J., M, K., K, M., JF, M., N, M., C, M., DK, M., V, M., SL, M., R, P., NR, P., N, R., M, S. R., G, R., R, S. G., M, S., & JB, B. (2026). Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?. The Journal of clinical endocrinology and metabolism. https://doi.org/10.1210/clinem/dgag290

Source records

pubmed · retrieved 2026-09-26T01:04:32.542Z